Is serputinib/serpatinib currently included in medical insurance?

Selpercatinib is a highly selective RET inhibitor, mainly used in the treatment of tumors related to RET gene fusion or mutation, including non-small cell lung cancer (NSCLC), thyroid cancer (TC) and medullary thyroid cancer (MTC). Today, with the rapid development of precision medicine, the emergence of RET target drugs has filled the gap of long-term lack of effective targeting solutions for this type of patients, making personalized treatment further mature. According to overseas guidelines and research data, seputinib has gradually become the first-line option for patients with RET-driven tumors due to its clear molecular target and good oral availability, showing potential advantages in terms of treatment tolerance and long-term remission.

At present, there are original research drugs in circulation in China, with a specification of 80mg*56 pills per box, and the market price exceeds 10,000 yuan. Due to the high pricing of drugs, the biggest concern for many patients is whether they have been included in the medical insurance list. According to the latest public information, Seputinib has not yet been included in the reimbursement scope of the national medical insurance. If patients need to use it for a long time, the financial burden will still be large. Compared with some common targeted drugs that have been included in medical insurance, as a newly launched innovative drug, the medical insurance access of seputinib needs to comprehensively consider many factors such as the size of the patient population, clinical value and price negotiation process.

As China gradually increases its support in the field of rare mutant tumors, Seputinib is expected to enter the medical insurance negotiation stage in the future. Once included in medical insurance, patients' medication accessibility will be greatly improved, which will also help promote the popularization of precision treatment models. For patients currently receiving or planning to receive treatment, it is recommended to pay close attention to the National Reimbursement Directory and consult with the treating physician about the feasibility of alternatives or patient assistance programs. Globally, it has become a trend for innovative targeted drugs to gradually enter medical insurance, and the prospects of seputinib in China's medical insurance are worth looking forward to.

Reference:https://en.wikipedia.org/wiki/Selpercatinib